Spindiag (Life Sciences Class 2017-4, Freiburg) addresses the challenge of patients introducing drug-resistant bacteria into hospitals, allowing to test on the spot whether or not a patient needs to be quarantined before entering a hospital.

Spindiag’s response to COVID-19: The diagnostics company developing point-of-care solutions to control infectious diseases, is working on a rapid test for coronavirus and has just received €6M in development support from the state of Baden-Wuerttemberg.

Source: German Accelerator